Baidu
map

Clin oral invest:两种MADS治疗OSA的效果

2017-12-16 MedSci MedSci原创

本研究的目的是确定两种下颌前移装置(MAD)治疗效果的差异

本研究的目的是确定两种下颌前移装置(MAD)治疗效果的差异。

材料与方法:在这项回顾性队列研究中,所用的两种装置是MAD型"Somnodent-Flex"(MAD1)和MAD型"Herbst"(MAD2)。共有137名患者参与了这项研究,其中67名患者接受了MAD1治疗,70名患者接受了MAD2。阻塞性睡眠呼吸暂停(OSA)使用MAD的指征是基于多导睡眠图检查,符合CBO指南。 MAD治疗的有效性通过第二次多导睡眠图检查(用原位MAD)来确定。呼吸暂停低通气指数(AHI)是在第一次和第二次多导睡眠图检查中记录的。通过这些值的变化来确定其有效性。

结果:对于两种MAD,在T1和T2上发现AHI显着降低:F(1,134)= 140,850,p <0.001。两种MAD的平均差异都与T1相关。在校正这个协方差之后,两种MAD在AHI值方面没有显着差异:F(1,134)= 1160,p = 0,283。

MAD1和MAD2的有效性在AHI值方面没有显着差异。

原始出处:

Francis Emma Verburg, et al. The effectiveness of two types of MADS for OSA therapy. Clinical oral investigations. 2017 December. doi:10.1007/s00784-017-2290-0

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2050989, encodeId=f380205098946, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jun 05 10:37:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029503, encodeId=860b202950366, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Thu Feb 01 12:37:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020306, encodeId=6a80202030643, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Thu Jan 25 03:37:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349765, encodeId=7ec41349e65af, content=<a href='/topic/show?id=3d0d134904c' target=_blank style='color:#2F92EE;'>#OSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13490, encryptionId=3d0d134904c, topicName=OSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon Dec 18 03:37:00 CST 2017, time=2017-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269848, encodeId=74bb269848ea, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Dec 16 12:49:08 CST 2017, time=2017-12-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2050989, encodeId=f380205098946, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jun 05 10:37:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029503, encodeId=860b202950366, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Thu Feb 01 12:37:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020306, encodeId=6a80202030643, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Thu Jan 25 03:37:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349765, encodeId=7ec41349e65af, content=<a href='/topic/show?id=3d0d134904c' target=_blank style='color:#2F92EE;'>#OSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13490, encryptionId=3d0d134904c, topicName=OSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon Dec 18 03:37:00 CST 2017, time=2017-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269848, encodeId=74bb269848ea, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Dec 16 12:49:08 CST 2017, time=2017-12-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2050989, encodeId=f380205098946, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jun 05 10:37:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029503, encodeId=860b202950366, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Thu Feb 01 12:37:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020306, encodeId=6a80202030643, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Thu Jan 25 03:37:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349765, encodeId=7ec41349e65af, content=<a href='/topic/show?id=3d0d134904c' target=_blank style='color:#2F92EE;'>#OSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13490, encryptionId=3d0d134904c, topicName=OSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon Dec 18 03:37:00 CST 2017, time=2017-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269848, encodeId=74bb269848ea, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Dec 16 12:49:08 CST 2017, time=2017-12-16, status=1, ipAttribution=)]
    2018-01-25 小几洁
  4. [GetPortalCommentsPageByObjectIdResponse(id=2050989, encodeId=f380205098946, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jun 05 10:37:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029503, encodeId=860b202950366, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Thu Feb 01 12:37:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020306, encodeId=6a80202030643, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Thu Jan 25 03:37:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349765, encodeId=7ec41349e65af, content=<a href='/topic/show?id=3d0d134904c' target=_blank style='color:#2F92EE;'>#OSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13490, encryptionId=3d0d134904c, topicName=OSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon Dec 18 03:37:00 CST 2017, time=2017-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269848, encodeId=74bb269848ea, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Dec 16 12:49:08 CST 2017, time=2017-12-16, status=1, ipAttribution=)]
    2017-12-18 柳叶一刀
  5. [GetPortalCommentsPageByObjectIdResponse(id=2050989, encodeId=f380205098946, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jun 05 10:37:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029503, encodeId=860b202950366, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Thu Feb 01 12:37:00 CST 2018, time=2018-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2020306, encodeId=6a80202030643, content=<a href='/topic/show?id=1584134451c' target=_blank style='color:#2F92EE;'>#Oral#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13445, encryptionId=1584134451c, topicName=Oral)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIpeueeYB1kem1yfEZrSYKBdZBoqac9USf0RxIgRICBIyDn4licyiaiakNnobeCDVpvwqaWgwTNeLRHA/132, createdBy=bb5e2500127, createdName=小几洁, createdTime=Thu Jan 25 03:37:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349765, encodeId=7ec41349e65af, content=<a href='/topic/show?id=3d0d134904c' target=_blank style='color:#2F92EE;'>#OSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13490, encryptionId=3d0d134904c, topicName=OSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon Dec 18 03:37:00 CST 2017, time=2017-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269848, encodeId=74bb269848ea, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Dec 16 12:49:08 CST 2017, time=2017-12-16, status=1, ipAttribution=)]
    2017-12-16 1ddf0692m34(暂无匿称)

    学习了.涨知识

    0

相关资讯

Am J Resp Crit Care:快速眼动睡眠期间OSA与心血管疾病相关性分析!

主要发生在REM睡眠期间的严重OSA与复合心血管终点的发病率较高有关,但仅限于心血管疾病患者。

Am J Resp Crit Care:认知正常老年人的OSA严重程度会影响淀粉样蛋白负担!

在认知正常的老年人样本中,OSA与2年随访中淀粉样蛋白负荷增加有关。OSA的睡眠碎片和/或间歇性缺氧可能是潜在的机制。如果证实,OSA的临床干预可能有助于预防认知正常老年人脑脊液中淀粉样蛋白的积聚。

SCI REP:肥厚型心肌病伴OSA患者存在肾小球滤过率下降的风险!

由此可见,该研究的结果表明肥厚型心肌病伴有OSA患者存在eGFR下降的风险。

Eur Respir J:CPAP治疗对阻塞性睡眠呼吸暂停合并冠状动脉疾病患者结局的影响!

由此可见,采用CPAP治疗的OSA合并CAD患者与无OSA的患者相比MACCEs的风险并未增加。

Anesth Analg:阻塞性睡眠呼吸暂停患者心脏手术后的结局:比较研究的系统评价和Meta分析

阻塞性睡眠呼吸暂停(OSA)是心脏手术患者常见的合并症,并可能使患者容易发生术后并发症。本meta分析的目的是明确接受心脏手术的OSA患者发生术后并发症的证据。

Eur Heart J:持续气道正压通气治疗在预防OSA患者心血管事件中的作用!

在夜间CPAP使用超过4小时的患者中CPAP治疗可能会降低MACE和卒中的风险。需要额外的随机试验强制要求CPAP治疗时间来证实这一效果。

Baidu
map
Baidu
map
Baidu
map